Revelation Biosciences, Inc. REVB
0.87
0.00
0.00%
as of 25 Sep
- Market cap
- $3.5M
- P/E
- 0.0×
Follow REVB
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.86 | 0.19 | 0.89 | 1.22 | 2.18 | 3.43 | 5.41 |
Net Debt/EBITDA |
— | 0.00 | 3.69 | 0.11 | 0.48 | 1.39 | 0.82 | 1.18 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.00 | 0.13 | 0.93 | 1.04 | 60.57 | 1.22 | 0.56 |
Capex/Depreciation |
— | — | — | (7.86) | 0.00 | 0.00 | (0.69) | 0.00 |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | (0.01%) | 57.25% | 413.94% | (2,272.74%) | (3.12%) | (264.85%) | (219.10%) | |
| — | (31.72%) | (4.40%) | (31.46%) | (287.04%) | (1.36%) | (159.69%) | (163.31%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 100.00% | 58.60% | 10,477.97% | (1,029.04%) | (1.81%) | (319.40%) | (168.32%) |
Research and Development Expense of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | 0.00 | (0.09) | 0.00 | (28,048.50) | (6,071.92) | (1,310.04) | (13.32) |
Cash per Share |
— | 0.00 | 0.22 | 0.00 | 13,132.50 | 9,993.08 | 464.21 | 17.23 |
Shareholders Equity per Share |
— | (0.01) | (2.36) | 0.00 | 2,631.25 | 5,539.75 | 336.31 | 14.27 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.01) | (2.36) | 0.00 | 2,631.25 | 5,539.75 | 336.31 | 14.27 |
Free Cash Flow |
— | — | (0.22) | (11.22) | (11.22) | (7.29) | (18.34) | (8.27) |
Working Capital |
— | 0.00 | (2.78) | (0.23) | 0.96 | 6.58 | 4.65 | 8.81 |
Capital Expenditures |
— | — | — | (0.13) | — | — | (0.02) | — |
Net Current Asset Value |
— | 0.00 | (79.20) | (0.23) | 0.96 | 6.58 | 4.65 | 8.09 |
| Other line items | ||||||||
Quick Ratio |
— | 0.00 | 0.16 | 0.60 | 1.18 | 2.15 | 3.40 | 5.36 |
Depreciation/Fixed assets |
— | — | — | 0.15 | 0.28 | 0.38 | 0.50 | 1.50 |
Cash ROIC |
— | 0.00% | 4.20% | (953.52%) | (179.36%) | (39.44%) | (163.98%) | (42.37%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | 0.00 | (0.09) | 0.00 | (28,048.50) | (6,071.92) | (1,308.66) | (13.32) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.37) | 0.00 |
Average Payables |
— | 0.03 | 0.03 | 0.32 | 0.58 | 0.96 | 1.07 | 0.68 |
Average Assets |
— | 0.01 | 37.09 | 38.10 | 3.77 | 8.86 | 9.42 | 9.10 |
Average Common Equity |
— | 33.91 | (2.85) | (2.90) | 0.48 | 3.85 | 5.68 | 6.78 |
Capex to Sales |
— | — | — | 0.00 | — | — | 0.00 | — |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates